Cleo Diagnostics Ltd (ASX:COV)

Australia · Delayed Price · Currency is AUD

0.620

-0.005 (-0.80%)

Last updated: Apr 29, 2026, 3:00 PM AEST

55.00% (1Y)

Market Cap	83.49M
Revenue (ttm)	2.56M
Net Income (ttm)	-4.03M
Shares Out	136.86M
EPS (ttm)	-0.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	211,609
Average Volume	202,418
Open	0.625
Previous Close	0.625
Day's Range	0.610 - 0.625
52-Week Range	0.315 - 0.900
Beta	0.41
RSI	54.15
Earnings Date	May 26, 2026

About Cleo Diagnostics

Cleo Diagnostics Ltd, a biotechnology company, focuses on the development and commercializing of non-invasive blood tests to detect ovarian cancer in Australia. The company offers CleoDX pre-surgical triage tests which measures a combination of five biomarkers in serum to provide an accurate determination of malignancy risk prior to surgical referral. It also focuses on developing and testing intellectual property, testing the IP, and securing patents. Cleo Diagnostics Ltd was incorporated in 2021 and is based in Melbourne, Australia. [Read more]

Industry Medical Devices

Sector Healthcare

Founded 2021

Country Australia

Stock Exchange Australian Securities Exchange

Ticker Symbol COV

Full Company Profile

Financial Performance

In fiscal year 2025, Cleo Diagnostics's revenue was 845,172, an increase of 300.91% compared to the previous year's 210,812. Losses were -4.00 million, 6.38% more than in 2024.

Financial Statements

News

There is no news available yet.